Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2025 Earnings Call Transcript August 5, 2025Rhythm Pharmaceuticals, Inc. misses on earnings expectations.
Rhythm Pharmaceuticals Inc. (RYTM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,604,483 | $354,147,281 | 3.44% | |
| 2. | RA Capital Management Peter Kolchinsky | 5,561,359 | $351,422,275 | -9% | 5.92% |
| 3. | Perceptive Advisors Joseph Edelman | 2,418,299 | $152,812,314 | -6% | 5.67% |
| 4. | Driehaus Capital Richard Driehaus | 1,269,952 | $80,248,267 | -13% | 0.64% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,250,870 | $79,042,475 | +151% | 0.41% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.17 | 10,000 | $201,713.00 | 111,335 | 2021-03-30 | Filing | |
| $26.42 | 378,501 | $9,999,996.42 | 3,074,893 | 2018-06-25 | Filing | |
| $17.00 | 100,000 | $1,700,000.00 | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 100,000 | $1,700,000.00 | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 550,000 | $9,350,000.00 | 4,909,956 | 2017-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $96.00 | 3,477 | $333,792.00 | 116,915 | 2025-08-13 | Filing | |
| $96.33 | 24,611 | $2,370,831.77 | 116,915 | 2025-08-12 | Filing | |
| $95.00 | 1,500 | $142,500.00 | 922 | 2025-08-12 | Filing | |
| $90.08 | 3,984 | $358,891.47 | 8,509 | 2025-08-11 | Filing | |
| $85.93 | 1,520 | $130,613.60 | 20,814 | 2025-07-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,267,538 | $396,045,725 | 0.01% | |
| 2. | 4,878,037 | $308,243,159 | 0.24% | |
| 3. | 3,589,114 | $226,796,115 | 0% | |
| 4. | 2,909,956 | $183,880,120 | 13.84% | |
| 5. | 1,953,441 | $123,437,950 | 0.01% |
News See All
Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals, Inc.
10 Best All-Time High Stocks to Buy According to Analysts
On July 31, Mike Wilson, Morgan Stanley's chief US equity strategist, joined CNBC Television to discuss the market performance amidst inflation concerns.
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00.
Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism
On May 29, analysts at Stifel raised their price target for Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) from $78 to $94 while maintaining their Buy rating for the company's shares.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript May 7, 2025Rhythm Pharmaceuticals, Inc. misses on earnings expectations.
10 Worst High-Risk High-Reward Growth Stocks To Buy
On March 14, Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the markets react to crises and what approach investors should take...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Call Transcript February 26, 2025Rhythm Pharmaceuticals, Inc. misses on earnings expectations.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
14 Worst 52-Week High Stocks to Buy According to Short Sellers
The start of the US Federal Reserve cutting cycle ushers a new era in the investment world after one of the longest bull runs.
Billionaire Hedge Funds
